Literature DB >> 33526484

Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses.

Thanh Bach1, Daryl J Murry2, Larissa V Stebounova1, Gregory Deye3, Patricia Winokur4, Guohua An5.   

Abstract

Oxfendazole is a potent veterinary benzimidazole anthelmintic under transition to humans for the treatment of multiple parasitic infectious diseases. The first-in-human study evaluating the disposition of oxfendazole and its metabolites in healthy adults following single ascending oral doses from 0.5 to 60 mg/kg of body weight shows that oxfendazole pharmacokinetics is substantially nonlinear, which complicates correlating oxfendazole dose to exposure. To quantitatively capture the relation between oxfendazole dose and exposure, a population pharmacokinetic model for oxfendazole and its metabolites, oxfendazole sulfone and fenbendazole, in humans was developed using a nonlinear mixed-effect modeling approach. Our final model incorporated mechanistic characterization of dose-limited bioavailability as well as different oxfendazole metabolic processes and provided insight into the significance of presystemic metabolism in oxfendazole and metabolite disposition. Oxfendazole clinical pharmacokinetics was best described by a one-compartment model with nonlinear absorption and linear elimination. Oxfendazole apparent clearance and apparent volume of distribution were estimated to be 2.57 liters/h and 35.2 liters, respectively, at the lowest dose (0.5 mg/kg), indicating that oxfendazole is a low extraction drug with moderate distribution. The disposition of both metabolites was adequately characterized by a one-compartment model with formation rate-limited elimination. Fenbendazole formation from oxfendazole was primarily through systemic metabolism, while both presystemic and systemic metabolism were critical to the formation of oxfendazole sulfone. Our model adequately captured the concentration-time profiles of both oxfendazole and its two metabolites in healthy adults over a wide dose range. The model can be used to predict oxfendazole disposition under new dosing regimens to support dose optimization in humans.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  anthelmintic drugs; first-in-human; oxfendazole; pharmacometric modeling; population PK analysis

Year:  2021        PMID: 33526484      PMCID: PMC8097468          DOI: 10.1128/AAC.02129-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

2.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

Authors:  Radojka M Savic; Daniël M Jonker; Thomas Kerbusch; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-26       Impact factor: 2.745

3.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

4.  Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study.

Authors:  Guohua An; Daryl J Murry; Kiran Gajurel; Thanh Bach; Greg Deye; Larissa V Stebounova; Ellen E Codd; John Horton; Armando E Gonzalez; Hector H Garcia; Dilek Ince; Denice Hodgson-Zingman; Effie Y H Nomicos; Thomas Conrad; Jessie Kennedy; Walt Jones; Robert H Gilman; Patricia Winokur
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 5.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

6.  A high oxfendazole dose to control porcine cysticercosis: pharmacokinetics and tissue residue profiles.

Authors:  L Moreno; M T Lopez-Urbina; C Farias; G Domingue; M Donadeu; B Dungu; H H García; L A Gomez-Puerta; C Lanusse; A E González
Journal:  Food Chem Toxicol       Date:  2012-07-26       Impact factor: 6.023

7.  Efficacy of a single high oxfendazole dose against gastrointestinal nematodes in naturally infected pigs.

Authors:  Luis Alvarez; Carlos Saumell; Luis Fusé; Laura Moreno; Laura Ceballos; Gilbert Domingue; Meritxell Donadeu; Baptiste Dungu; Carlos Lanusse
Journal:  Vet Parasitol       Date:  2013-01-12       Impact factor: 2.738

8.  Dose titration of oxfendazole against common nematodes of swine.

Authors:  R M Corwin; J A Kennedy; S E Pratt
Journal:  Am J Vet Res       Date:  1979-02       Impact factor: 1.156

9.  Effective, single-dose treatment or porcine cysticercosis with oxfendazole.

Authors:  A E Gonzales; H H Garcia; R H Gilman; C M Gavidia; V C Tsang; T Bernal; N Falcon; M Romero; M T Lopez-Urbina
Journal:  Am J Trop Med Hyg       Date:  1996-04       Impact factor: 2.345

10.  Treatment of porcine cysticercosis with albendazole.

Authors:  A E Gonzalez; H H Garcia; R H Gilman; M T Lopez; C Gavidia; J McDonald; J B Pilcher; V C Tsang
Journal:  Am J Trop Med Hyg       Date:  1995-11       Impact factor: 2.345

View more
  2 in total

1.  Comparing the performance of first-order conditional estimation (FOCE) and different expectation-maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model.

Authors:  Thanh Bach; Guohua An
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-04-21       Impact factor: 2.745

2.  Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis.

Authors:  Thanh Bach; Gregory A Deye; Ellen E Codd; John Horton; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.938

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.